Diversified Pipeline
Discovered Using Pharma.AI
Discovered Using Pharma.AI
INNOVATIVE AND ACCELERATED INTERNAL DRUG CANDIDATES
- 31Total Number of Programs
- 29Total Number of Targets
- 2Preclinical Candidates Nominated in 2021
- 9Preclinical Candidates Nominated in 2022
Programs below progressed beyond early pre-clinical. Many programs are available under CDA.
Contact bd@insilicomedicine.com for partnering opportunities
Target
Fibrosis
Immunology
Oncology
Other
Stage of development
Discovery
IND-enabling
Phase 1
Phase 2
Co-development
USA (FDA)
Out-licensed with Exclusive rights
Out-licensed
with Exclusive rights
with Exclusive rights
China (NMPA)
cMYC
EMT, FMT, fibroblast macrophage activation
Immune modulation
Idiopathic Pulmonary Fibrosis (IPF)
Epigenetics
Kidney Fibrosis
Immuno-Oncology
Immune modulation
ER+/HER2- breast cancer
Synthetic lethality
Solid Tumors
Synthetic lethality
MTAP-/- cancer
Virus replication
BRCA-mutant cancer
Mechanism
COVID-19
EPO induction and iron utilization
IPF (Inhalable)
Tumor cell proliferation
indication
Epithelial integrity & anti-inflammation
Anemia of Chronic Kidney Disease
Immune modulation
Solid Tumors
Tumor cell proliferation
Inflammatory Bowel Disease
Cell proliferation and survival
Solid Tumors
Mitotic arrest
Solid Tumors
Tumor cell proliferation
Solid Tumors
Chromosomally unstable Cancers
Solid Tumors
Idiopathic Pulmonary Fibrosis
COLLABORATIONS
AND PARTNERSHIPS
AND PARTNERSHIPS
The rapid progress of internal pipeline demonstrates the generative-AI driven drug discovery capabilities of our Pharma.AI platform consisting of Biology42, Chemistry42, and Medicine42.
Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.
Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.
TNIK
TNIK Inhibitor: Treating Fibrotic diseases of the Lung and Kidney
3CLPro
Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection
PHD
Proline Hydroxylase (PHD) Inhibitors: Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
QPCTL
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor: Novel cancer immunotherapy for COLD tumors
USP1
Ubiquitin Specific Protease 1 (USP1) Inhibitor for the treatment of BRCA-mutant cancer
MAT2A
Methionine adenosyltransferase 2α (MAT2A) Inhibitor: Treatment of MTAP Deficient Cancer
KAT6
KAT6 Inhibitor: Treatment of ER+/HER2- Breast Cancer
ENPP1
Ectonucleotide phosphodiesterase 1 (ENPP1) Inhibitor: Treating anti-PD-1/-L1 resistant cancers
DGKA
Diacylglycerol kinase A (DGKA) Inhibitor: Treating solid tumors in combination with checkpoint inhibitor
CDK12
Cyclin-dependent kinase 12 (CDK12) Inhibitor: Treating Tumors by Induction of BRCAness
TEAD
Pan-TEAD Inhibitor: Treating Mesothelioma, and Solid Tumors
FGFR2/3
FGFR2/3 Dual Inhibitor: Treatment of Solid Tumors
KIF18A
KIF18A Inhibitor: Treating chromosomally unstable cancers with TP53 mutations